Biofrontera Inc.
BFRI · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.00 | 0.00 | -0.00 |
| FCF Yield | -45.78% | -93.36% | -16.93% | -15.08% |
| EV / EBITDA | -0.87 | -1.94 | -4.48 | -1.09 |
| Quality | ||||
| ROIC | -380.25% | -75.08% | -15.30% | -56.24% |
| Gross Margin | 73.64% | 64.19% | 62.63% | 45.88% |
| Cash Conversion Ratio | 0.57 | 0.57 | 0.98 | 0.73 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.40% | 10.50% | 11.17% | 9.17% |
| Free Cash Flow Growth | 26.07% | -304.72% | 12.09% | 75.48% |
| Safety | ||||
| Net Debt / EBITDA | 0.44 | -0.80 | 0.88 | 0.35 |
| Interest Coverage | -44.17 | -37.89 | -31.13 | -551.11 |
| Efficiency | ||||
| Inventory Turnover | 0.59 | 0.47 | 0.71 | 0.75 |
| Cash Conversion Cycle | 30.34 | 136.69 | 130.03 | 131.70 |